Compare Wells Fargo & Co (WFC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wells Fargo & Co vs GeneDx Holdings Corp — how do they compare? Wells Fargo & Co trades at $88.61 (market cap $264.66B), while GeneDx Holdings Corp trades at $81.89 (market cap $2.44B). The key difference: Wells Fargo & Co is far larger — about 108.5× GeneDx Holdings Corp's market cap, and Wells Fargo & Co pays a 2.29% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| WFC | WGS | |
|---|---|---|
Market Cap | $264.66B | $2.44B |
Sector | Financials | Technology |
52-Week High | $96.40 | $167.51 |
52-Week Low | $73.42 | $34.51 |
Dividend Yield | 2.29% | — |
Enterprise Value | — | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wells Fargo (WFC) trades at $87.55, up 0.34% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 12.72, net income margin of 25.97%, and ROE of 13.13%. Recent earnings beat expectations in Q2 2026, and the company is expanding digital services like tokenized deposits. Analyst consensus is mixed but leans positive, with a price target of $97.64.
The outlook for WFC is favorable, driven by earnings growth and strategic innovations, though risks include volatile cash flows and economic sensitivity. Upside potential exists if the company meets future earnings and maintains profitability, but investors should monitor execution and macroeconomic factors.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
